HeartForce is pleased to announce that it has successfully collected datasets for 330 patients in their clinical trial in Uzbekistan. Seismocardiography and gyrocardiography, for a non-invasive coronary artery disease (CAD) diagnosis, were compared to coronary artery calcium computed tomography (CAC), coronary computed tomography (CCTA), and invasive coronary angiography (ICA).
The datasets were collected between the months of April 2021 to June 2021 in Tashkent and Karshi. HeartForce is confident that patient numbers will see a steady increase moving forward and estimates to have the study complete by November 2021 – at which point a comprehensive CAD report will be released. Included in the report will be vibration signal comparisons, before and after stent procedures, as well as an in-depth, evidenced based, analysis for the determination of the overall CAD accuracy, sensitivity, and specificity of our screening technology in comparison to CAC, CCTA, and ICA.